Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) fell 3.4% during mid-day trading on Monday . The stock traded as low as $19.50 and last traded at $19.50, with a volume of 107,926 shares trading hands. The stock had previously closed at $20.19.

NTLA has been the subject of several recent research reports. Credit Suisse Group AG initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price target for the company. Leerink Swann initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price target for the company. Wedbush initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price target for the company. Jefferies Group initiated coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued a “hold” rating and a $33.00 price target for the company. Finally, Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $35.50.

The company has a 50-day moving average of $20.41 and a 200-day moving average of $23.47. The firm’s market capitalization is $697.24 million.

In other Intellia Therapeutics news, major shareholder Institutes For Biomed Novartis bought 277,777 shares of the business’s stock in a transaction on Wednesday, May 11th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $4,999,986.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Bros. Advisors Lp Baker bought 200,000 shares of the business’s stock in a transaction on Wednesday, May 11th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $3,600,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.